The pathologic hypertrophy of hypertensive heart disease is related to the quality, not the quantity, of myocardium; the presence of fi brosis is inevitably linked to structural and functional insuffi ciencies with increased cardiovascular risk. Elevations in plasma aldosterone that are inappropriate relative to dietary sodium, or relative aldosteronism, are accompanied by suppressed plasma renin activity, elevation in arterial pressure, and dyshomeostasis of divalent cations. The accompanying hypocalcemia, hypomagnesemia, and hypozincemia of aldosteronism contribute to the appearance of secondary hyperparathyroidism. Parathyroid hormone-mediated intracellular calcium overloading of cardiac myocytes and mitochondria leads to the induction of oxidative stress and molecular pathways associated with cardiomyocyte necrosis and scarring of myocardium, whereas the dyshomeostasis of zinc compromises antioxidant defenses. This dyshomeostasis of calcium and zinc, intrinsically coupling prooxidant calcium and antioxidant zinc, raises the prospect for therapeutic strategies designed to mitigate intracellular calcium overloading while enhancing zinc-mediated antioxidant defenses, thus preventing adverse myocardial remodeling with fi brosis, associated diastolic dysfunction, and cardiac arrhythmias.
Introduction
Concentric left ventricular hypertrophy (LVH) accompanies intermittent or sustained elevations in arterial pressure [1, 2] . Despite comparable enlargement in LV mass seen with isometric exercise training or hypertensive heart disease (HHD), the latter is frequently associated with abnormalities in LV diastolic function [3] [4] [5] . Moreover, the LVH that accompanies HHD is a common risk factor for other adverse cardiovascular events, including ventricular arrhythmias [2, 6, 7] , suggesting that it is not the quantity of myocardium, but rather the pathologic quality of its structure, that is detrimental to its function.
Morphologic studies of the myocardium in HHD, obtained postmortem or by endomyocardial biopsy, reveal an abnormal accumulation of fi brillar collagen [5, [8] [9] [10] . Two distinct morphologic patterns of fi brosis have emerged: Reparative fi brosis, or microscopic scarring, is a footprint of prior cardiomyocyte necrosis. The programmed death of these cells is not accompanied by either infl ammatory-cell or fi broblast infi ltration, and therefore apoptosis does not beget a fi brous tissue response. Reactive perivascular fi brosis unequivocally follows the vasculopathy of the intramural coronary circulation, from which fi brillar collagen extends to initiate interstitial fi brosis. The extent to which the myocardium is remodeled by fi brous tissue infi ltration correlates well with the degree of LVH and abnormalities of myocardial stiffness [4, 5, 10] .
Among hypertensive African Americans, LVH is an important prognostic risk factor for ventricular arrhythmias independent of coronary artery disease [11, 12] . African American patients most commonly have lowrenin hypertension, in which plasma aldosterone levels are not fully suppressed by dietary sodium loading. The clinical presentation of this relative aldosteronism includes symptoms and signs of expanded intravascular and extravascular volumes due to reduced urinary sodium excretion. Referred to as "wet" hypertension, this condition is managed by a diuretic with proven effi cacy in correcting edema and controlling blood pressure [13, 14] . This article reviews studies that address pathways leading to cardiomyocyte necrosis with scarring and relevant cardioprotective strategies that could prevent adverse myocardial remodeling in low-renin hypertension associated with elevated or inappropriate levels of plasma aldosterone (hereafter referred to simply as aldosteronism).
Low-Renin Hypertension in Humans
Brunner et al. [13] categorized patients having essential hypertension into three groups (ie, low, normal, and high) based on plasma renin activity relative to urinary sodium excretion. Those with low renin activity, in whom aldosterone excretion failed to be suppressed during dietary sodium loading, were considered to have low-renin hypertension with a functional derangement in aldosterone secretion [15, 16] . These patients tend to retain sodium and often present with salt-induced hypertension.
In studies reported in the 1980s, Resnick and coworkers [17] elucidated the features of the metabolic-hormonal profi le found in patients with low-renin hypertension: 1) reduced plasma renin activity coupled with inappropriate elevations in plasma aldosterone, which is not adequately suppressed by salt loading; 2) ionized hypocalcemia accompanied by elevations in serum parathyroid hormone (PTH); and 3) increased intracellular calcium (Ca 2+ )-for example, in platelets. These investigators proposed an association between calcium and sodium metabolism that contributes to the pathophysiology of salt-induced hypertension and to the blood pressure-lowering effects of oral calcium supplementation (which corrects the ionized hypocalcemia) as well as calcium channel blockade, which retards PTH-mediated intracellular calcium overloading. Secondary hyperparathyroidism (SHPT) is a well-recognized clinical feature of aldosteronism. Rossi et al. [18] demonstrated that elevations in serum PTH found in patients with primary aldosteronism could be reduced by either spironolactone treatment or adrenal surgery. The increased melanin content of the skin of African Americans serves as a natural sunscreen and consequently results in a prevalence of hypovitaminosis D (often of marked severity), which compromises calcium homeostasis and predisposes these patients to hypocalcemia and subsequent SHPT [19] [20] [21] .
Hypomagnesemia is also a recognized feature of aldosteronism; it too is corrected by spironolactone or adrenal surgery [22, 23] . In addition to the ionized hypocalcemia and hypomagnesemia that accompany increased urinary and fecal losses of these divalent cations, studies by others in subsequent years have identifi ed a concomitant dyshomeostasis of zinc with hypozincemia [24, 25] .
Therefore, the metabolic-hormonal profi le shown in Table 1 for low-renin hypertension with aldosteronism depicts a dyshomeostasis of multiple nutrients, including calcium, magnesium, zinc, and vitamin D. Other factors that may play critical roles in the genesis of compromised calcium stores and the appearance of SHPT in African Americans include reduced dietary calcium intake because of lactose intolerance and active avoidance of dairy products as well as a preference for a high-sodium diet that enhances urinary calcium excretion. A high-salt diet normally suppresses plasma renin activity in healthy persons, but it fails to do so in those with low-renin hypertension. Instead, it is accompanied by increased excretory losses of calcium, with the resultant calciuria predisposing to ionized hypocalcemia and, in turn, SHPT, with resorption of bone invoked to restore extracellular calcium homeostasis. Over time, osteopenia and osteoporosis accompany the hypercalciuria of long-term dietary sodium excess, predisposing to atraumatic bone fractures [26] . Hence, the link between sodium and alterations in calcium metabolism, such as the augmented urinary calcium excretion promoted by increased urinary sodium, is again noted, similar to the link between salt-induced hypertension and low-renin hypertension.
"Calcium Paradoxes" of Low-Renin Human Hypertension
In 1964, Fleckenstein advanced his hypothesis that excessive intracellular calcium accumulation is cytotoxic to cardiomyocytes and proposed that this intracellular calcium overloading would accompany the acute administration of a catecholamine or chronic elevations of a calciotropic hormone such as vitamin D. These fi ndings were reported in a 1967 article elaborating on the cardioprotective properties of a calcium channel blocker, which attenuated calcium entry in response to a hormonal challenge [27] . Fujita and Palmieri [28] reported that elevations in plasma PTH, elicited in response to falling extracellular calcium, in which SHPT is invoked to promote bone mineral resorption to compensate for hypocalcemia, would lead to excessive intracellular calcium accumulation. They applied the term "calcium paradox" to this intracellular calcium overloading contemporaneous with falling extracellular calcium and proposed that it may be an underlying pathophysiologic mechanism involved in various diseases, including hypertension. Several years earlier, Massry and Smogorzewski [29] identifi ed the role of PTH-mediated intracellular calcium overloading that accompanies the SHPT associated with chronic renal failure; it also involves cardiomyocytes and vascular smooth muscle cells. Increased calcium entry is mediated 
